Bayer's Leadership Prepares For First Innovative Drug Launch In China Ahead Of U.S.
This article was originally published in PharmAsia News
Executive Summary
BEIJING - After obtaining regulatory approval for an innovative new anticoagulant in Beijing while a simultaneously filed application is still being reviewed by the U.S. FDA in Washington, DC, the leadership of Bayer Schering Pharma AG is now crafting a plan for the release of the drug in China ahead of the United States
You may also be interested in...
Bayer Taps Pfizer Emerging Markets Head To Lead Health Care Division
Pfizer’s Olivier Brandicourt, who has specialized in emerging markets and infectious diseases, inherits Bayer’s health care division, which is in the midst of several product launches and has few near-term patent expirations. Bayer has one of the largest exposures to emerging markets among large pharma companies.
Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt
Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt